IRIS
FERRARO, Giuseppa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.317
NA - Nord America 2.986
AS - Asia 1.364
SA - Sud America 361
Continente sconosciuto - Info sul continente non disponibili 70
AF - Africa 43
OC - Oceania 1
Totale 8.142
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.908
RU - Federazione Russa 1.758
SG - Singapore 536
CN - Cina 440
SE - Svezia 404
IE - Irlanda 353
BR - Brasile 310
DE - Germania 144
HK - Hong Kong 141
IT - Italia 134
FR - Francia 133
UA - Ucraina 102
PL - Polonia 73
GB - Regno Unito 72
FI - Finlandia 69
VN - Vietnam 62
IN - India 48
CA - Canada 32
BD - Bangladesh 23
AR - Argentina 19
BE - Belgio 18
AT - Austria 17
ZA - Sudafrica 16
TR - Turchia 15
MX - Messico 14
CO - Colombia 13
ID - Indonesia 13
IQ - Iraq 12
NL - Olanda 10
IL - Israele 9
MA - Marocco 8
PK - Pakistan 8
SA - Arabia Saudita 8
AE - Emirati Arabi Uniti 7
JM - Giamaica 7
JP - Giappone 7
PH - Filippine 7
EC - Ecuador 5
UZ - Uzbekistan 5
DZ - Algeria 4
ES - Italia 4
ET - Etiopia 4
HN - Honduras 4
JO - Giordania 4
PE - Perù 4
VE - Venezuela 4
AZ - Azerbaigian 3
CR - Costa Rica 3
CW - ???statistics.table.value.countryCode.CW??? 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
EG - Egitto 3
LT - Lituania 3
LV - Lettonia 3
NI - Nicaragua 3
RO - Romania 3
RS - Serbia 3
TT - Trinidad e Tobago 3
AL - Albania 2
BO - Bolivia 2
CI - Costa d'Avorio 2
CL - Cile 2
DK - Danimarca 2
GP - Guadalupe 2
GT - Guatemala 2
IR - Iran 2
KE - Kenya 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
PS - Palestinian Territory 2
SC - Seychelles 2
TH - Thailandia 2
TN - Tunisia 2
AI - Anguilla 1
AU - Australia 1
BG - Bulgaria 1
BY - Bielorussia 1
CH - Svizzera 1
EU - Europa 1
GR - Grecia 1
GY - Guiana 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MN - Mongolia 1
MY - Malesia 1
NP - Nepal 1
PR - Porto Rico 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 8.077
Salva come PNG Salva come JPEG
Città #
Moscow 461
Ashburn 444
Dublin 352
Singapore 319
Chandler 309
Dallas 244
Nyköping 205
Jacksonville 199
San Jose 162
Beijing 160
Hong Kong 141
The Dalles 87
New York 80
Council Bluffs 75
Los Angeles 68
Warsaw 66
Ann Arbor 63
Dearborn 58
Cambridge 51
Princeton 51
Medford 49
Lauterbourg 44
Des Moines 43
Messina 41
Munich 41
Boardman 34
Buffalo 30
Jinan 25
São Paulo 23
Woodbridge 22
Frankfurt am Main 21
Tianjin 21
Pune 19
Brussels 18
Ho Chi Minh City 18
San Mateo 17
Vienna 17
Lancaster 16
Chicago 14
Shenyang 14
Turku 14
Belo Horizonte 13
Brooklyn 13
Wilmington 13
Atlanta 12
Guangzhou 12
Montreal 12
Redondo Beach 12
Santa Clara 12
Nanjing 11
Orem 11
Phoenix 11
Hebei 10
Houston 10
Johannesburg 10
Zhengzhou 10
Chennai 9
Hanoi 9
Campinas 8
London 8
Manchester 8
Baghdad 7
Columbus 7
Denver 7
Dong Ket 7
Mexico City 7
Rio de Janeiro 7
San Francisco 7
Shenzhen 7
Amsterdam 6
Da Nang 6
Goiânia 6
Grammichele 6
Jakarta 6
Milan 6
Mumbai 6
Ningbo 6
Shanghai 6
Taizhou 6
Washington 6
Ankara 5
Augusta 5
Brasília 5
Changsha 5
Dhaka 5
Fort Washington 5
Helsinki 5
Joinville 5
Miami 5
Seattle 5
Stockholm 5
Tashkent 5
Tokyo 5
Addis Ababa 4
Boston 4
Curitiba 4
Dubai 4
El Paso 4
Fuzhou 4
Haikou 4
Totale 4.565
Salva come PNG Salva come JPEG
Nome #
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 252
Prognostic value of methlylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS) promoter, and p53 codon 72 variants and survival in advanced non-small cell lung cancer (NSCLC). 249
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 240
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 230
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 222
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 203
Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases 194
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 192
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 191
Preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes for the assessment of metastasis risk in breast cancer (BC). 188
A new method for titration of oral transmucosal fentanyl citrate (OTFC) starting dose in cancer patients. 186
Beta=interferon in the treatment of 14 patie nts with advanced colorectal carcinoma. J Exp Pathol. 1987 Summer;3(4):603-5. No abstract available. PMID: 3454807 [PubMed - indexed for MEDLINE] 182
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 180
Correction: Androgen Receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in Triple-Negative Breast Cancer (TNBC) patients 178
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: 171
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data 170
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother. 1999 Feb;11(1):74-7. PMID: 10078785 [PubMed - indexed for MEDLINE] 169
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data. 166
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: A phase II study 165
Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study. 165
Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients 164
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 163
Correlation between serum magnesium levels and skin toxicity during cetuximab treatment in squamous cell carcinoma of head and neck cancer (SCCHN): the role of weekly intravenous magnesium supplementation. 163
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 162
Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors ? 159
Role of Androgen Receptor (AR), Ki 67 and E-cadherin as prognostic markers in Triple Negative Breast Cancer (TNBC) 156
Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients 153
Metastasis risk assessment in breast cancer (BC): a preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes 151
RANDOMISED PHASE II TERTIARY CHEMOPREVENTION TRIAL FOR COLORECTAL ADENOMA IN 24 PATIENTS WITH COLORECTAL CANCER TREATED WITH CELECOXIB 151
Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. 149
Incidence and preferential localizations of bone metastases: biomolecolar and clinical implications. 149
Uncommon breast metastatic site and eribulin responsiveness in a heavily pretreated patient 144
Pegylated liposomal doxorubicin in combination with gemcitabine in elderly women with locally advanced or metastatic breast cancer: safety and activity results of our clinical experience. 144
Early Breast Cancer HER2 positivo in postmenopausa: strategia terapeutica adiuvante 143
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study) 141
NSCLC and HER2: between lights and shadows 141
Effectiveness of the combination therapy with lisinopril, ivabradine and multivitamin supplementation in anthracycline-induced severe cardiotoxicity 136
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile. 131
New biomarkers to predict response to pemetrexed-based chemotherapy in non small cell lung cancer: from 5,10-methylenetetrahydrofolate reductase promises to miRNAs revolution. 130
Risk evaluation in breast cancer: a preliminary study of pre-metastatic niche in 252 lymphnodes 129
Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series. 124
Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study. 122
Ruolo di Trastuzumab nella terapia adiuvante del carcinoma mammario operabile. 120
Neoplasie della testa collo nell’ anziano 116
Pre-metastatic niche identification in node negative breast cancer to assess metastasis risk. Pathological and clinical implications 110
Role of MTHFR polymorphisms as predictive markers of acute toxicity during 5-fluorouracil based chemotherapy for colorectal cancer: Preliminary data. 108
Safety of trastuzumab-containing therapies in elderly women with metastatic breast cancer. 103
Temozolamide plus oral vinorelbine in the treatment of brain metastases from solid tumours in heavily pre- treated patients. 95
SAFETY OF PEGILATED LIPOSOMAL DOXORUBICIN AND GEMCITABINE IN ELDERLY WOMEN (>65 YEARS)WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER 91
Invecchiamento e cancro. 88
The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. 69
null 52
null 37
null 33
null 22
Totale 8.142
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.235
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.235
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022323 0 0 0 0 14 6 23 9 5 99 57 110
2022/20231.137 87 118 49 105 83 104 18 88 444 2 29 10
2023/2024313 18 50 15 27 16 124 30 17 0 4 1 11
2024/20251.030 8 9 19 68 47 42 12 181 268 60 98 218
2025/20263.577 181 197 243 186 289 804 469 514 487 127 41 39
2026/2027443 36 110 132 154 11 0 0 0 0 0 0 0
Totale 8.142